Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Percutaneous Radiofrequency Ablation with or without Chemolipiodolization for Early-stage Hepatocellular Carcinoma: A Propensity Score-matched Analysis

Version 1 : Received: 3 October 2021 / Approved: 4 October 2021 / Online: 4 October 2021 (10:19:37 CEST)

How to cite: Takaki, K.; Nakano, M.; Fukumori, K.; Yano, Y.; Zaizen, Y.; Niizeki, T.; Kuwaki, K.; Fukahori, M.; Sakaue, T.; Yoshimura, S.; Nakazaki, M.; Torimura, T. Percutaneous Radiofrequency Ablation with or without Chemolipiodolization for Early-stage Hepatocellular Carcinoma: A Propensity Score-matched Analysis. Preprints 2021, 2021100038 (doi: 10.20944/preprints202110.0038.v1). Takaki, K.; Nakano, M.; Fukumori, K.; Yano, Y.; Zaizen, Y.; Niizeki, T.; Kuwaki, K.; Fukahori, M.; Sakaue, T.; Yoshimura, S.; Nakazaki, M.; Torimura, T. Percutaneous Radiofrequency Ablation with or without Chemolipiodolization for Early-stage Hepatocellular Carcinoma: A Propensity Score-matched Analysis. Preprints 2021, 2021100038 (doi: 10.20944/preprints202110.0038.v1).

Abstract

We aimed to compare prognostic factors for overall survival (OS) following percutaneous radiofrequency ablation (PRFA) with or without chemolipiodolization (CL) for early-stage hepatocellular carcinoma (HCC) using propensity score-matched analysis. We enrolled 221 patients with early-stage HCC who received PRFA with (n = 76) or without (n = 145) CL in Saga Central Hospital between April 2004 and December 2020. No significant difference was observed in OS between PRFA with and without CL cohorts (median survival time [MST]: 5.4 vs. 4.5 years; p = 0.0806). To reduce confounding effects, 108 patients were selected using propensity score-matched analysis (n = 54 for each treatment). No significant difference was observed in OS between the cohorts (MST: 3.6 vs. 4.0 years; p = 0.5474). After stratification according to tumor size, no significant difference was observed in OS for patients with tumor size ≥20 mm between PRFA with and without CL cohorts (MST: 3.4 vs. 3.5 years; p = 0.8236). PRFA with CL was not a significant prognostic factor in both univariate and multivariate analyses (p = 0.5477 and 0.9600, respectively). Our findings suggest that PRFA with CL does not demonstrate longer prognostic effects than PRFA without CL in early-stage HCC, regardless of tumor size.

Keywords

hepatocellular carcinoma; percutaneous radiofrequency ablation; chemolipiodolization; risk factors; propensity score-matched analysis

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.